Integrin CD11b activation drives anti-tumor innate immunity

Michael C. Schmid, Samia Q. Khan, Megan M. Kaneda, Paulina Pathria, Ryan Shepard, Tiani L. Louis, Sudarshan Anand, Gyunghwi Woo, Chris Leem, M. Hafeez Faridi, Terese Geraghty, Anugraha Rajagopalan, Seema Gupta, Mansoor Ahmed, Roberto I. Vazquez-Padron, David A. Cheresh, Vineet Gupta, Judith A. Varner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins, a family of adhesion receptors that includes integrin CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid cell recruitment to tumors but instead controls myeloid cell polarization and tumor growth. CD11b activation promotes pro-inflammatory macrophage polarization by stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents Let7a expression and induces cMyc expression, leading to immune suppressive macrophage polarization, vascular maturation, and accelerated tumor growth. Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 (LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor growth in animal models of murine and human cancer. These studies identify CD11b as negative regulator of immune suppression and a target for cancer immune therapy.

Original languageEnglish (US)
Article number5379
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

immunity
Innate Immunity
Integrins
Tumors
tumors
Chemical activation
activation
macrophages
Macrophages
Polarization
Neoplasms
Myeloid Cells
polarization
cells
Growth
cancer
wound healing
animal models
regulators
infectious diseases

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Schmid, M. C., Khan, S. Q., Kaneda, M. M., Pathria, P., Shepard, R., Louis, T. L., ... Varner, J. A. (2018). Integrin CD11b activation drives anti-tumor innate immunity. Nature Communications, 9(1), [5379]. https://doi.org/10.1038/s41467-018-07387-4

Integrin CD11b activation drives anti-tumor innate immunity. / Schmid, Michael C.; Khan, Samia Q.; Kaneda, Megan M.; Pathria, Paulina; Shepard, Ryan; Louis, Tiani L.; Anand, Sudarshan; Woo, Gyunghwi; Leem, Chris; Faridi, M. Hafeez; Geraghty, Terese; Rajagopalan, Anugraha; Gupta, Seema; Ahmed, Mansoor; Vazquez-Padron, Roberto I.; Cheresh, David A.; Gupta, Vineet; Varner, Judith A.

In: Nature Communications, Vol. 9, No. 1, 5379, 01.12.2018.

Research output: Contribution to journalArticle

Schmid, MC, Khan, SQ, Kaneda, MM, Pathria, P, Shepard, R, Louis, TL, Anand, S, Woo, G, Leem, C, Faridi, MH, Geraghty, T, Rajagopalan, A, Gupta, S, Ahmed, M, Vazquez-Padron, RI, Cheresh, DA, Gupta, V & Varner, JA 2018, 'Integrin CD11b activation drives anti-tumor innate immunity', Nature Communications, vol. 9, no. 1, 5379. https://doi.org/10.1038/s41467-018-07387-4
Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL et al. Integrin CD11b activation drives anti-tumor innate immunity. Nature Communications. 2018 Dec 1;9(1). 5379. https://doi.org/10.1038/s41467-018-07387-4
Schmid, Michael C. ; Khan, Samia Q. ; Kaneda, Megan M. ; Pathria, Paulina ; Shepard, Ryan ; Louis, Tiani L. ; Anand, Sudarshan ; Woo, Gyunghwi ; Leem, Chris ; Faridi, M. Hafeez ; Geraghty, Terese ; Rajagopalan, Anugraha ; Gupta, Seema ; Ahmed, Mansoor ; Vazquez-Padron, Roberto I. ; Cheresh, David A. ; Gupta, Vineet ; Varner, Judith A. / Integrin CD11b activation drives anti-tumor innate immunity. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{94383cd3e22744c9a3dc02256de583a1,
title = "Integrin CD11b activation drives anti-tumor innate immunity",
abstract = "Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins, a family of adhesion receptors that includes integrin CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid cell recruitment to tumors but instead controls myeloid cell polarization and tumor growth. CD11b activation promotes pro-inflammatory macrophage polarization by stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents Let7a expression and induces cMyc expression, leading to immune suppressive macrophage polarization, vascular maturation, and accelerated tumor growth. Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 (LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor growth in animal models of murine and human cancer. These studies identify CD11b as negative regulator of immune suppression and a target for cancer immune therapy.",
author = "Schmid, {Michael C.} and Khan, {Samia Q.} and Kaneda, {Megan M.} and Paulina Pathria and Ryan Shepard and Louis, {Tiani L.} and Sudarshan Anand and Gyunghwi Woo and Chris Leem and Faridi, {M. Hafeez} and Terese Geraghty and Anugraha Rajagopalan and Seema Gupta and Mansoor Ahmed and Vazquez-Padron, {Roberto I.} and Cheresh, {David A.} and Vineet Gupta and Varner, {Judith A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-07387-4",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Integrin CD11b activation drives anti-tumor innate immunity

AU - Schmid, Michael C.

AU - Khan, Samia Q.

AU - Kaneda, Megan M.

AU - Pathria, Paulina

AU - Shepard, Ryan

AU - Louis, Tiani L.

AU - Anand, Sudarshan

AU - Woo, Gyunghwi

AU - Leem, Chris

AU - Faridi, M. Hafeez

AU - Geraghty, Terese

AU - Rajagopalan, Anugraha

AU - Gupta, Seema

AU - Ahmed, Mansoor

AU - Vazquez-Padron, Roberto I.

AU - Cheresh, David A.

AU - Gupta, Vineet

AU - Varner, Judith A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins, a family of adhesion receptors that includes integrin CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid cell recruitment to tumors but instead controls myeloid cell polarization and tumor growth. CD11b activation promotes pro-inflammatory macrophage polarization by stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents Let7a expression and induces cMyc expression, leading to immune suppressive macrophage polarization, vascular maturation, and accelerated tumor growth. Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 (LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor growth in animal models of murine and human cancer. These studies identify CD11b as negative regulator of immune suppression and a target for cancer immune therapy.

AB - Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins, a family of adhesion receptors that includes integrin CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid cell recruitment to tumors but instead controls myeloid cell polarization and tumor growth. CD11b activation promotes pro-inflammatory macrophage polarization by stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents Let7a expression and induces cMyc expression, leading to immune suppressive macrophage polarization, vascular maturation, and accelerated tumor growth. Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 (LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor growth in animal models of murine and human cancer. These studies identify CD11b as negative regulator of immune suppression and a target for cancer immune therapy.

UR - http://www.scopus.com/inward/record.url?scp=85058844750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058844750&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-07387-4

DO - 10.1038/s41467-018-07387-4

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 5379

ER -